CTOs on the Move

The Center for Professional Innovation and Educa

www.cfpie.com

 
The Center for Professional Innovation and Education is a Wayne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cfpie.com
  • 992 Old Eagle School Rd Ste 913
    Wayne, PA USA 19087
  • Phone: 610.688.1708

Executives

Name Title Contact Details

Similar Companies

West Pharmaceuitcals

West Pharmaceuitcals is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AAI Pharmaceutical

AAI Pharmaceutical is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ultivue

Ultivue develops innovative reagent-based solutions that maximize the biological information available from cells and tissue samples. The company`s technology is being used to elucidate biological pathways and to validate clinically-relevant biomarkers. Ultivue is based in Cambridge, MA. Our culture provides an exceptional work environment fostering innovation and collaboration to make a difference collectively. Ultivue`s employees are bright, flexible, and driven to create meaningful impact through our work. We work at a fast pace, but support each other achieve the work/life balance that helps us thrive as a company. Our entrepreneurial culture relies on contributions and input from all. Our bench of experienced managers provides mentoring and support to ensure front line staff make the most of their unique talents and energy.

ChemDiv

ChemDiv is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Imvax

The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company`s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.